Evidence map›Paper›PMID 40666455›Full record

ArticleACS medicinal chemistry letters2025

Effects of Oxygen Atom Position in Linear Side Chains of Ansellone Analogues on HIV Latency-Reversing Activity.

Kanae Nakahara, Naoki Kishimoto, Tae Yasutake, Yutaro Hanatani, Shogo Misumi, Mitsuhiro Arisawa, Kenichi Murai

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kanae NakaharaGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka Suita, Osaka, 565-0871, Japan.
Naoki KishimotoDepartment of Environmental and Molecular Health Sciences, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
Tae YasutakeDepartment of Environmental and Molecular Health Sciences, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
Yutaro HanataniSchool of Pharmaceutical Sciences, Wakayama Medical University, 25-1 Shichibancho, Wakayama, Wakayama 640-8156, Japan.
Shogo MisumiDepartment of Environmental and Molecular Health Sciences, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
Mitsuhiro ArisawaGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka Suita, Osaka, 565-0871, Japan.ORCID https://orcid.org/0000-0002-7937-670X
Kenichi MuraiGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka Suita, Osaka, 565-0871, Japan.ORCID https://orcid.org/0000-0002-1689-6492

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiretroviral therapy can manage HIV infections, but a cure remains elusive owing to viral latency. The "shock and kill" strategy uses latency-reversing agents (LRAs) to reactivate viral production toward eliminating latent HIV. However, developing novel LRA scaffolds remains a critical challenge. This study focused on a structurally simplified hydrobenzopyran analogue of ansellone A, a natural product with latency-reversing activity. To investigate the influence of incorporating ether oxygen into the alkyl chain, thought to anchor to the biological membrane, on the biological activity, we designed and synthesized a series of hydrobenzopyran analogs with varying oxygen positions in their lipophilic side chains. Biological evaluation in J-Lat 10.6 and TZM-bl cells revealed that the oxygen atom position did not considerably influence the HIV latency-reversing activity. Furthermore, none of the compounds affected cell viability. These findings suggest that ether-containing hydrobenzopyran derivatives represent a viable and synthetically flexible scaffold for the development of novel LRAs.

Indexed as

human immunodeficiency viruslatency-reversing activitynatural product analogstructure activity relationship

Identifiers

PMID40666455
PMCPMC12257371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.